Patent Settlements and Medicare Negotiation: What Leverage Does Pharma Have To ‘Game’ Price Reform?
Executive Summary
Brand drug companies might be able to use patent settlements with generic and biosimilar makers to get out of the drug price negotiations that will be created under the US legislation nearing enactment, but sponsors could run into regulatory and antitrust obstacles.
You may also be interested in...
Merck’s Januvia, Medicare Pricing, And The Meaning of Patent Life
Recent patent extension win for Januvia illustrates the dilemma that will be faced by manufacturers of older, single-source drugs that are chosen for price negotiation in the Medicare program.
Merck’s Januvia, Medicare Pricing, And The Meaning of Patent Life
Recent patent extension win for Januvia illustrates the dilemma that will be faced by manufacturers of older, single-source drugs that are chosen for price negotiation in the Medicare program.
Medicare Price ‘Negotiation’ : Manufacturer Compliance Gets Tougher Enforcement Provision
As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.